Identification	O
of	O
novel	O
macrolides	B:C0282563
with	O
antibacterial	B:C0544570
,	O
anti-inflammatory	O
and	O
type	B:C0021747
I	I:C0021747
and	O
III	B:C0021747
IFN	I:C0021747
-	O
augmenting	B:C0243095
activity	I:C0243095
in	O
airway	B:C0458827
epithelium	B:C0014609
Exacerbations	B:C0349790
of	I:C0349790
asthma	I:C0349790
and	O
COPD	B:C0740304
are	O
triggered	O
by	O
rhinoviruses	B:C0035473
.	O

Uncontrolled	O
inflammatory	B:C1512758
pathways	I:C1512758
,	O
pathogenic	O
bacterial	O
burden	O
and	O
impaired	O
antiviral	B:C1155328
immunity	I:C1155328
are	O
thought	O
to	O
be	O
important	O
factors	O
in	O
disease	O
severity	O
and	O
duration	O
.	O

Macrolides	B:C0282563
including	O
azithromycin	B:C0052796
are	O
often	O
used	O
to	O
treat	O
the	O
above	O
diseases	B:C0012634
,	O
but	O
exhibit	O
variable	O
levels	O
of	O
efficacy	O
.	O

Ideally	O
,	O
new	O
treatment	O
alternatives	O
should	O
suppress	O
unwanted	O
inflammation	B:C0021368
,	O
but	O
spare	O
beneficial	O
antiviral	B:C1155328
immunity	I:C1155328
.	O

In	O
the	O
present	O
study	B:C0947630
,	O
we	O
screened	O
225	O
novel	O
macrolides	B:C0282563
and	O
tested	O
them	O
for	O
enhanced	O
antiviral	B:C1321382
activity	I:C1321382
against	O
rhinovirus	B:C0035473
,	O
as	O
well	O
as	O
anti-inflammatory	B:C0243095
activity	I:C0243095
and	O
activity	O
against	O
Gram	B:C0018154
-	I:C0018154
positive	I:C0018154
and	O
Gram	B:C0018150
-	I:C0018150
negative	I:C0018150
bacteria	I:C0018150
.	O

Primary	O
bronchial	B:C1711178
epithelial	I:C1711178
cells	I:C1711178
were	O
grown	O
from	O
10	O
asthmatic	O
individuals	O
and	O
the	O
effects	O
of	O
macrolides	B:C0282563
on	O
rhinovirus	B:C0035473
replication	B:C0042774
were	O
also	O
examined	B:C0332128
.	O

Another	O
30	O
structurally	O
similar	O
macrolides	B:C0282563
were	O
also	O
examined	B:C0332128
.	O

The	O
oleandomycin	B:C0028923
derivative	O
Mac5	B:C0028923
,	O
compared	O
with	O
azithromycin	B:C0052796
,	O
showed	O
superior	O
induction	O
(	O
up	O
to	O
5	O
-	O
fold	O
,	O
EC	O
50	O
=	O
5	O
-	O
11	O
μM	O
)	O
of	O
rhinovirus	B:C0035473
-	O
induced	O
type	B:C1334081
I	I:C1334081
IFNβ	I:C1334081
,	O
type	B:C1334085
III	I:C1334085
IFNλ1	I:C1334085
and	O
type	B:C1334085
III	I:C1334085
IFN	I:C1334085
λ	I:C1334085
2/	I:C1334085
3	I:C1334085
mRNA	B:C0035696
and	O
the	O
IFN	B:C0021747
-	O
stimulated	O
genes	B:C0017337
viperin	B:C1539703
and	O
MxA	B:C1417510
,	O
yet	O
had	O
no	O
effect	O
on	O
IL	B:C1334122
-	I:C1334122
6	I:C1334122
and	O
IL	B:C1366571
-	I:C1366571
8	I:C1366571
mRNA	B:C0035696
.	O

Mac5	B:C0028923
also	O
suppressed	O
rhinovirus	B:C0035473
replication	B:C0042774
at	O
48	O
h	O
,	O
proving	O
antiviral	B:C1321382
activity	I:C1321382
.	O

Mac5	B:C0028923
showed	O
antibacterial	B:C0544570
activity	I:C0544570
against	O
Gram	B:C0018154
-	I:C0018154
positive	I:C0018154
Streptococcus	B:C0038410
pneumoniae	I:C0038410
;	O
however	O
,	O
it	O
did	O
not	O
have	O
any	O
antibacterial	B:C0544570
properties	I:C0544570
compared	O
with	O
azithromycin	B:C0052796
when	O
used	O
against	O
Gram	B:C0018150
-	I:C0018150
negative	I:C0018150
Escherichia	B:C0014834
coli	I:C0014834
(	O
as	O
a	O
model	O
organism	O
)	O
and	O
also	O
the	O
respiratory	O
pathogens	O
Pseudomonas	B:C0033809
aeruginosa	I:C0033809
and	O
non-typeable	O
Haemophilus	B:C0018483
influenzae	I:C0018483
.	O

Further	O
non-toxic	O
Mac5	B:C0028923
derivatives	O
were	O
identified	O
with	O
various	O
anti-inflammatory	O
,	O
antiviral	B:C1321382
and	O
antibacterial	B:C0544570
activities	I:C0544570
.	O

The	O
data	O
support	O
the	O
idea	O
that	O
macrolides	B:C0282563
have	O
antiviral	B:C1321382
properties	I:C1321382
through	O
a	O
mechanism	O
that	O
is	O
yet	O
to	O
be	O
ascertained	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
macrolides	B:C0282563
can	O
be	O
developed	O
with	O
anti-inflammatory	O
,	O
antibacterial	B:C0544570
and	O
antiviral	B:C1321382
activity	I:C1321382
and	O
show	O
surprising	O
versatility	O
depending	O
on	O
the	O
clinical	O
need	O
.	O

